F344/NSlc |
blood glucose level |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
blood glucose amount |
male |
211 days
| 7 |
78.0 |
mg/dl |
2.6 |
6.88 |
oral glucose tolerance test |
0 |
oral glucose |
0 |
min |
ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) |
12770 |
311 |
F344.OLETF-(D14Rat23-D14Rat12)/Tj |
body weight |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
body mass |
male |
211 days
| 11 |
425.3 |
g |
5.3 |
17.58 |
body weighing method |
0.0 |
oral glucose |
0 |
min |
|
12797 |
311 |
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj |
body weight |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
body mass |
male |
211 days
| 11 |
423.2 |
g |
7.3 |
24.21 |
body weighing method |
0.0 |
oral glucose |
0 |
min |
|
12803 |
311 |
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj |
serum insulin level |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
blood insulin amount |
male |
211 days
| 11 |
0.0 |
mg/dl |
0.0 |
0.0 |
oral glucose tolerance test |
0.0 |
oral glucose |
0 |
min |
ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) |
67478 |
311 |
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj |
serum leptin level |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
blood leptin amount |
male |
211 days
| 11 |
5.82 |
ng/ml |
0.59 |
1.96 |
enzyme linked immunosorbent assay |
0.0 |
oral glucose |
7 |
days |
ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) |
67486 |
311 |
F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj |
blood glucose level |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
blood glucose amount |
male |
211 days
| 11 |
87.7 |
mg/dl |
3.2 |
10.61 |
oral glucose tolerance test |
0.0 |
oral glucose |
0 |
min |
ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) |
12798 |
311 |
F344/NSlc |
serum insulin level |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
blood insulin amount |
male |
211 days
| 7 |
0.0 |
mg/dl |
0.0 |
0.0 |
oral glucose tolerance test |
0.0 |
oral glucose |
0 |
min |
ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) |
67475 |
311 |
F344/NSlc |
serum leptin level |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
blood leptin amount |
male |
211 days
| 7 |
5.46 |
ng/ml |
1.06 |
2.8 |
enzyme linked immunosorbent assay |
0.0 |
oral glucose |
7 |
days |
ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) |
67483 |
311 |
F344.OLETF-(D14Rat23-D14Rat12)/Tj |
serum leptin level |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
blood leptin amount |
male |
211 days
| 11 |
6.28 |
ng/ml |
0.51 |
1.69 |
enzyme linked immunosorbent assay |
0.0 |
oral glucose |
7 |
days |
ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) |
67485 |
311 |
F344/NSlc |
body weight |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
body mass |
male |
211 days
| 7 |
393.6 |
g |
6.2 |
16.4 |
body weighing method |
|
oral glucose |
0 |
min |
|
12785 |
311 |
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj |
body weight |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
body mass |
male |
211 days
| 7 |
368.7 |
g |
8.7 |
23.02 |
body weighing method |
|
oral glucose |
0 |
min |
|
12791 |
311 |
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj |
serum leptin level |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
blood leptin amount |
male |
211 days
| 7 |
2.8 |
ng/ml |
0.54 |
1.43 |
enzyme linked immunosorbent assay |
0.0 |
oral glucose |
7 |
days |
ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) |
67484 |
311 |
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj |
blood glucose level |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
blood glucose amount |
male |
211 days
| 7 |
78.7 |
mg/dl |
3.4 |
9.0 |
oral glucose tolerance test |
0 |
oral glucose |
0 |
min |
ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) |
12786 |
311 |
F344.OLETF-(D7Mgh16-D7Mgh20)/Tj |
serum insulin level |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
blood insulin amount |
male |
211 days
| 7 |
0.0 |
mg/dl |
0.0 |
0.0 |
oral glucose tolerance test |
0.0 |
oral glucose |
0 |
min |
ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) |
67476 |
311 |
F344.OLETF-(D14Rat23-D14Rat12)/Tj |
serum insulin level |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
blood insulin amount |
male |
211 days
| 11 |
0.0 |
mg/dl |
0.0 |
0.0 |
oral glucose tolerance test |
0.0 |
oral glucose |
0 |
min |
ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) |
67477 |
311 |
F344.OLETF-(D14Rat23-D14Rat12)/Tj |
blood glucose level |
specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) |
Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21. |
blood glucose amount |
male |
211 days
| 11 |
82.5 |
mg/dl |
3.5 |
11.61 |
oral glucose tolerance test |
0 |
oral glucose |
0 |
min |
ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN) |
12792 |
311 |